ESC 365 - De-escalation vs. early cessation of DAPT for patients at high bleeding risk

ESC Professional Premium Access

De-escalation vs. early cessation of DAPT for patients at high bleeding risk

Session: Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions

Topic: Antiplatelet Agents

Speaker: Doctor P. Rath (Hyderabad, IN)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Pratap Chandra Rath

Apollo hospitals, Hyderabad (India)

1 presentation

0 follower

3 more presentations in this session

When should we prolong DAPT beyond 12 months?

Speaker: Doctor M. Das (Kolkata, IN)

Is aspirin the preferred monotherapy after DAPT?

Speaker: Professor B. Rocca (Casamassima, IT)

Machine learning to determine the optimal mode and duration of DAPT

Speaker: Doctor B. Vogel (New York, US)

Access the full session

Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions

Speakers: Doctor P. Rath, Doctor M. Das, Professor B. Rocca, Doctor B. Vogel

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources